Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains

Mark D Gonzalez; Meghan A Wallace; Tiffany Hink; Erik R Dubberke; Carey-Ann D Burnham

doi:10.1128/AAC.01670-15

Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains

Antimicrob Agents Chemother. 2015 Nov;59(11):7084-5. doi: 10.1128/AAC.01670-15. Epub 2015 Aug 17.

Authors

Mark D Gonzalez¹, Meghan A Wallace¹, Tiffany Hink², Erik R Dubberke², Carey-Ann D Burnham³

Affiliations

¹ Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
² Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
³ Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, Missouri, USA cburnham@path.wustl.edu.

Abstract

Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection of Clostridium difficile isolates and report uniformly high MICs (≥256 μg/ml) to C/T.

MeSH terms

Anti-Bacterial Agents / pharmacology*
Cephalosporins / pharmacology*
Clostridioides difficile / classification
Clostridioides difficile / drug effects*
Clostridioides difficile / genetics
Microbial Sensitivity Tests
Penicillanic Acid / analogs & derivatives*
Penicillanic Acid / pharmacology
Phylogeny
Tazobactam

Substances

Anti-Bacterial Agents
Cephalosporins
ceftolozane
Penicillanic Acid
Tazobactam